Show simple item record

dc.contributor.authorKontovounisios, C
dc.contributor.authorQiu, S
dc.contributor.authorRasheed, S
dc.contributor.authorDarzi, A
dc.contributor.authorTekkis, P
dc.date.accessioned2018-02-15T12:24:04Z
dc.date.issued2017-09
dc.identifier.citationUpdates in surgery, 2017, 69 (3), pp. 397 - 402
dc.identifier.issn2038-131X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1116
dc.identifier.eissn2038-3312
dc.identifier.doi10.1007/s13304-017-0464-6
dc.description.abstractColorectal cancer screening programs aim at early detection of cancer to reduce incidence rates and mortality. The objective of this study is to identify the role of neurotensin in the endoscopic screening of high-risk population for developing colorectal neoplasia. Blood samples from patients referred for urgent colonoscopy to investigate symptoms suspicious of colorectal cancer were collected. Blood neurotensin levels were measured using enzyme-linked immunosorbent assay. Colonoscopy findings were used as reference for determining the diagnostic accuracy of blood neurotensin. The study comprised 26 patients in total: 12 healthy and 14 with colon pathology (13 high-grade dysplasia adenomatous polyps, 1 adenocarcinoma). There were no statistically significant differences in the clinical and biochemical parameters between colon pathology and healthy group except neurotensin levels. Pathology in colon was associated with 3.7-fold increase in NT levels. In multivariate analysis, patients with pathology in colon have increased serum neurotensin levels compared to controls adjusted for age, gender, BMI and co-morbidities. The value of 12.93 pg/ml is associated with 87.5% sensitivity and 91.7% specificity for discriminating the colon pathology from normal colonic epithelium (p = 0.001). Neurotensin plasma values differentiate healthy people from patients suffering from colonic pathologies such as adenomatous polyps and cancer. The use of neurotensin as a potential endoscopic screening tool for identifying high-risk population for developing colorectal cancer is promising, but much has to be done before it is validated in larger scale prospective studies.
dc.formatPrint-Electronic
dc.format.extent397 - 402
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectAdenomatous Polyps
dc.subjectAdenocarcinoma
dc.subjectColorectal Neoplasms
dc.subjectNeurotensin
dc.subjectColonoscopy
dc.subjectSensitivity and Specificity
dc.subjectCase-Control Studies
dc.subjectProspective Studies
dc.subjectFeasibility Studies
dc.subjectPilot Projects
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectYoung Adult
dc.subjectBiomarkers, Tumor
dc.titleThe role of neurotensin as a novel biomarker in the endoscopic screening of high-risk population for developing colorectal neoplasia.
dc.typeJournal Article
dcterms.dateAccepted2017-05-04
rioxxterms.versionofrecord10.1007/s13304-017-0464-6
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfUpdates in surgery
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume69
pubs.embargo.termsNot known
dc.contributor.icrauthorDarzi, Araen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0